Impact of COVID-19 on prescribing patterns and treatment selection of disease modifying therapies in multiple sclerosis.

Background: Certain classes of multiple sclerosis (MS) disease modifying therapies (DMTs) have been associated with an increased risk of severe COVID-19, resulting in prescribers considering changes in their practice habits during the COVID-19 pandemic. This study assessed for differences in prescribing patterns of DMTs along with the reason(s) for modification of therapy over time.

Methods: A retrospective review of medical records at Johns Hopkins Health System was performed.